FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to immunology. Disclosed are an antibody and its antigen-binding fragment, capable of binding to CXCR3, as well as a conjugate and a pharmaceutical composition containing same. Also described is the use of an antibody or a fragment thereof for the prevention, treatment or suppression of the progression of newly diagnosed type 1 diabetes (T1D) and an in vitro method for detecting the presence or determination of CXCR3 concentration in a test sample.
EFFECT: present invention can find further application in the therapy of diseases associated with CXCR3.
17 cl, 28 dwg, 13 ex, 13 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODIES TO THE THOMSEN-FRIEDENREICH ANTIGEN | 2015 |
|
RU2699717C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| NEW ANTIBODIES INHIBITING C-MET DIMERISATION AND USING THEM | 2008 |
|
RU2552161C2 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| ANTIBODIES RAISED AGAINST α-INTERFERON | 2002 |
|
RU2314317C2 |
| HUMANISED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6, METHODS AND USES THEREOF | 2010 |
|
RU2596925C2 |
| IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| ANTIBODIES AGAINST CTLA4 AND THEIR USE | 2017 |
|
RU2779312C2 |
